Personalis to Present at the 21st Annual Needham Virtual Healthcare Conference
Get Alerts PSNL Hot Sheet
Join SI Premium – FREE
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 21st Annual Needham Virtual Healthcare Conference on Wednesday, April 13, 2022 at 2:15 p.m. Eastern Time.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis’ Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005944/en/
Investor Relations Contact:
Caroline Corner
[email protected]
415-202-5678
Media Contact:
Jennifer Temple
[email protected]
www.personalis.com
650-752-1300
Source: Personalis, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- A-CAP Announces Agreement to Divest its Interest in Vasco da Gama SAF
- Daycare Expert Timothy R. Norris Explains Before and After School Care in Harrisburg, PA, in HelloNation
- Dynamic Frontier Holdings Receives Regulatory Approvals to Acquire Teghout CJSC
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Needham & Company, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share